These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16447118)

  • 1. Seroreversion in subjects receiving antiretroviral therapy during acute/early HIV infection.
    Hare CB; Pappalardo BL; Busch MP; Karlsson AC; Phelps BH; Alexander SS; Bentsen C; Ramstead CA; Nixon DF; Levy JA; Hecht FM
    Clin Infect Dis; 2006 Mar; 42(5):700-8. PubMed ID: 16447118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune control of HIV-1 after early treatment of acute infection.
    Rosenberg ES; Altfeld M; Poon SH; Phillips MN; Wilkes BM; Eldridge RL; Robbins GK; D'Aquila RT; Goulder PJ; Walker BD
    Nature; 2000 Sep; 407(6803):523-6. PubMed ID: 11029005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete HIV type 1 antibody evolution and seroreversion in acutely infected individuals treated with early antiretroviral therapy.
    Kassutto S; Johnston MN; Rosenberg ES
    Clin Infect Dis; 2005 Mar; 40(6):868-73. PubMed ID: 15736021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B; Cooper DA; Lampe FC; Perrin L; Clumeck N; Phillips AN; Goh LE; Lindback S; Sereni D; Gazzard B; Montaner J; Stellbrink HJ; Lazzarin A; Ponscarme D; Staszewski S; Mathiesen L; Smith D; Finlayson R; Weber R; Wegmann L; Janossy G; Kinloch-de Loes S;
    Clin Infect Dis; 2007 Aug; 45(3):381-90. PubMed ID: 17599319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative potency of three antiretroviral therapy regimes in primary HIV infection.
    Fidler S; Fraser C; Fox J; Tamm N; Griffin JT; Weber J
    AIDS; 2006 Jan; 20(2):247-52. PubMed ID: 16511418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology.
    de Souza MS; Pinyakorn S; Akapirat S; Pattanachaiwit S; Fletcher JL; Chomchey N; Kroon ED; Ubolyam S; Michael NL; Robb ML; Phanuphak P; Kim JH; Phanuphak N; Ananworanich J;
    Clin Infect Dis; 2016 Aug; 63(4):555-61. PubMed ID: 27317797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection.
    Chiappini E; Galli L; Tovo PA; Gabiano C; Gattinara GC; Guarino A; Badolato R; Giaquinto C; Lisi C; de Martino M;
    AIDS; 2006 Jan; 20(2):207-15. PubMed ID: 16511413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.
    Gianella S; von Wyl V; Fischer M; Niederoest B; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF;
    Antivir Ther; 2011; 16(4):535-45. PubMed ID: 21685541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon?
    Madec Y; Boufassa F; Rouzioux C; Delfraissy JF; Meyer L;
    Clin Infect Dis; 2005 May; 40(9):1350-4. PubMed ID: 15825038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response.
    Zanchetta M; Anselmi A; Vendrame D; Rampon O; Giaquinto C; Mazza A; Accapezzato D; Barnaba V; De Rossi A
    Antivir Ther; 2008; 13(1):47-55. PubMed ID: 18389898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent humoral immune defect in highly active antiretroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection.
    Bekker V; Scherpbier H; Pajkrt D; Jurriaans S; Zaaijer H; Kuijpers TW
    Pediatrics; 2006 Aug; 118(2):e315-22. PubMed ID: 16847077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV RNA viral load and CD4+ T-cell counts in HIV-infected pregnant women with and without treatment discontinuation in early pregnancy.
    Tamburrini E; Ravizza M; Floridia M; Tibaldi C; Alberico S; Anzidei G; Maccabruni A; Meloni A; Antoni AD; Mori F; Dalzero S; Conservan V; Pinnetti C; Ferrazzi E;
    Antivir Ther; 2008; 13(4):519-27. PubMed ID: 18672530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
    Benson CA; Vaida F; Havlir DV; Downey GF; Lederman MM; Gulick RM; Glesby MJ; Wantman M; Bixby CJ; Rinehart AR; Snyder S; Wang R; Patel S; Mellors JW;
    J Infect Dis; 2006 Nov; 194(9):1309-18. PubMed ID: 17041858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early identification of seronegative human immunodeficiency virus type 1 infection with severe presentation.
    Chin BS; Lee SH; Kim GJ; Kee MK; Suh SD; Kim SS
    J Clin Microbiol; 2007 May; 45(5):1659-62. PubMed ID: 17344360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the interruption of antiretroviral treatment during pregnancy an additional major risk factor for mother-to-child transmission of HIV type 1?
    Galli L; Puliti D; Chiappini E; Gabiano C; Ferraris G; Mignone F; Viganò A; Giaquinto C; Genovese O; Anzidei G; Badolato R; Buffolano W; Maccabruni A; Salvini F; Cellini M; Ruggeri M; Manzionna M; Bernardi S; Tovo P; de Martino M;
    Clin Infect Dis; 2009 May; 48(9):1310-7. PubMed ID: 19309307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.